

Zydus Cadila Q1 Net profit up by 21%

Ahmedabad, 29th July 2008

For the first quarter ended June 30, 2008, Zydus Cadila reported a total income of Rs. 714 crore, up 25% from Rs. 572 crore in the corresponding quarter of the previous year on a consolidated basis. The net profit is up by 21% to Rs. 90 crore from Rs.74 crore in the first quarter of 2007-08.

The Income growth was mainly driven by 60% growth in formulation exports. Both, the U.S. business as well as the business in France posted a sales growth of 36%. The consumer business posted a healthy 26% growth.

During the quarter, Zydus Cadila announced two key overseas acquisitions. Making a foray into the 5th largest pharmaceutical market in Europe, the group acquired Laboratorios Combix in Spain. The group also acquired 70% stake in Simayla Pharmaceuticals of South Africa, which is Africa's largest drug market. Both acquisitions are expected to strengthen the group's global operations significantly.

The group also announced the first day launch of Venlafaxine Hydrochloride Tablets in the US upon receiving the final approval. The group received tentative approvals for Escitalopram Oxalate Tablets, Losartan Potassium and Hydrochlorthiazide Tablets, Anastrozole Tablets and approvals for Pravastatin Sodium Tablets and Benazepril Tablets during the quarter, taking the total number of approvals to 39. The group has so far filed 79 ANDAs and 59 DMFs.

The quarter also witnessed the group's foray into the Rs. 3500 crore nutraceutical segment with the setting up of a speciality division, Zydus Nutriva. The nutraceutical segment comprises haematinics, antioxidants, tonics, vitamins, multi vitamins, proteins, nutrients and calcium preparations.

During the quarter, the group initiated the restructuring of the Consumer Products Business. By grouping synergistic businesses into a single entity, the group aims to optimize the strengths of its consumer business, which can be more effectively leveraged.
